<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01512173</url>
  </required_header>
  <id_info>
    <org_study_id>V00400 GL 2 01 1A</org_study_id>
    <secondary_id>2011-003144-50</secondary_id>
    <nct_id>NCT01512173</nct_id>
  </id_info>
  <brief_title>Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo</brief_title>
  <official_title>A Randomised, Double Blind, Controlled, Multicentre Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Dermatology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Dermatology</source>
  <brief_summary>
    <textblock>
      There is an unsatisfied medical need for a first-line treatment of localized uncomplicated
      proliferating Infantile Hemangioma with a good benefit/risk profile.

      Pierre Fabre Dermatologie has developed a new formulation of propranolol (V0400 GL 01A) which
      is a topical gel adapted to paediatric use.

      The objective of this study is to evaluate topical propranolol efficacy and safety in the
      management of localized hemangioma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete/nearly complete resolution of the Infantile Hemangioma at week 12.</measure>
    <time_frame>week 12</time_frame>
    <description>Complete/nearly complete resolution of the Infantile Hemangioma at week 12 compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>On-site parent(s) or guardian(s) qualitative assessments of efficacy</measure>
    <time_frame>week 2 , week 4, week 8, week 12 and week 24</time_frame>
    <description>categorical endpoints for Infantile Hemangioma evolution (4-points scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of efficacy 12 weeks after the end of treatment</measure>
    <time_frame>Week 24</time_frame>
    <description>Persistence of complete/nearly complete resolution of the Infantile Hemangioma at week 24 compared to week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile (descriptive analysis of AE)</measure>
    <time_frame>Day 0, week 2, week 4, week 8, week 12 and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local tolerance of the propranolol gel(description over time by treatment group)</measure>
    <time_frame>week 2, week 4, week 8 and week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Infantile Hemangioma</condition>
  <arm_group>
    <arm_group_label>propranolol gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propranolol gel</intervention_name>
    <description>Topical administration twice daily</description>
    <arm_group_label>propranolol gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Topical administration twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  only one proliferating Infantile Hemangioma present anywhere on the body except on the
             head, the neck, the hands and on the diaper area, with largest diameter diameter ≥ 1cm
             and ≤ 5 cm.

        Main Exclusion Criteria:

          -  more than one Infantile Hemangioma with largest diameter ≥ 1cm

          -  medically unstable health status that may interfere with his/her ability to complete
             the study

          -  Infantile Hemangioma requires, according to Investigator's judgment, a systemic
             treatment

          -  the patient has previously been administered treatment for IH or surgical and/or
             medical procedures (e.g. laser therapy) have been performed to treat the IH
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Days</minimum_age>
    <maximum_age>150 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Bordeaux Hôpital Pellegrin-Enfants - Unité de Dermatologie pédiatrique</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Vincent de Paul - Dermatologie Pédiatrique</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Est Hôpital mère enfant - Consultation des angiomes</name>
      <address>
        <city>Lyon Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Timone - Service de dermatologie</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Mère-Enfant - Service de Néonatologie et Réanimation Pédiatrique</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Necker enfants malades - Service de dermatologie</name>
      <address>
        <city>Paris</city>
        <zip>75517</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Etienne Hôpital Nord - Service de dermatologie</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse Hôpital des enfants - Département cardio-pédiatrique</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Clocheville - Centre de Pédiatrie Gatien</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pomorskie Centrum Traumatologii im. M. Kopernika w Gdańsku Klinika Chirurgii i Urologii Dzieci i Młodzieży GUMed</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytet Medyczny w Łodzi Klinika Chirurgii i Onkologii Dziecięcej</name>
      <address>
        <city>Lodz</city>
        <zip>91-738</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut &quot;Pomnik-Centrum Zdrowia Dziecka&quot;, Klinika Onkologii</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Pau de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infantil Niño Jesús</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28056</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2012</study_first_submitted>
  <study_first_submitted_qc>January 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <last_update_submitted>October 29, 2014</last_update_submitted>
  <last_update_submitted_qc>October 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Propranolol gel</keyword>
  <keyword>Hemangioma</keyword>
  <keyword>capillary neoplasm</keyword>
  <keyword>vascular tissue</keyword>
  <keyword>neoplasm by histologic type</keyword>
  <keyword>neoplasm</keyword>
  <keyword>therapeutic uses</keyword>
  <keyword>pharmacologic actions</keyword>
  <keyword>adrenergic beta-antagonists</keyword>
  <keyword>adrenergic antagonist</keyword>
  <keyword>adrenergics agent</keyword>
  <keyword>neurotransmitter agent</keyword>
  <keyword>molecular mechanism of pharmacological action</keyword>
  <keyword>physiological effects of drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Hemangioma, Capillary</mesh_term>
    <mesh_term>Port-Wine Stain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

